Last Price
0.695
Today's Change
+0.035 (5.30%)
Day's Change
0.675 - 0.722
Trading Volume
12,551,637
Market Cap
855 Million
Shares Outstanding
1 Billion
Avg Volume
3,572,034
Avg Price (50 Days)
0.48
Avg Price (200 Days)
0.54
PE Ratio
-1.36
EPS
-0.51
Earnings Announcement
26-Feb-2025
Previous Close
0.66
Open
0.68
Day's Range
0.675 - 0.722
Year Range
0.3125 - 0.815
Trading Volume
12,551,637
1 Day Change
5.30%
5 Day Change
13.93%
1 Month Change
40.40%
3 Month Change
87.84%
6 Month Change
12.10%
Ytd Change
23.01%
1 Year Change
98.57%
3 Year Change
-45.28%
5 Year Change
-81.11%
10 Year Change
284.35%
Max Change
204.23%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.